Apria, Inc. (NYSE:APR) EVP Mark E. Litkovitz Sells 2,458 Shares

Apria, Inc. (NYSE:APR) EVP Mark E. Litkovitz sold 2,458 shares of the business’s stock in a transaction dated Monday, October 11th. The shares were sold at an average price of $32.40, for a total value of $79,639.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

APR opened at $32.41 on Thursday. The stock has a 50-day moving average of $35.52 and a 200-day moving average of $31.21. Apria, Inc. has a 52-week low of $20.07 and a 52-week high of $40.00. The company has a current ratio of 1.21, a quick ratio of 1.18 and a debt-to-equity ratio of 215.95.

Apria (NYSE:APR) last posted its quarterly earnings data on Thursday, August 5th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.17. The business had revenue of $286.28 million for the quarter, compared to analyst estimates of $280.18 million. As a group, equities research analysts forecast that Apria, Inc. will post 1.63 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of APR. Blackstone Group Inc. acquired a new position in shares of Apria during the 1st quarter worth about $676,242,000. Bank of New York Mellon Corp acquired a new position in shares of Apria during the 1st quarter worth about $36,528,000. American Century Companies Inc. acquired a new position in shares of Apria during the 2nd quarter worth about $33,765,000. Deerfield Management Company L.P. Series C acquired a new position in shares of Apria during the 1st quarter worth about $33,516,000. Finally, Burgundy Asset Management Ltd. acquired a new position in shares of Apria during the 1st quarter worth about $28,031,000. 94.99% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have commented on APR shares. Zacks Investment Research downgraded Apria from a “buy” rating to a “hold” rating in a research note on Wednesday, October 6th. started coverage on Apria in a research note on Wednesday, June 30th. They issued a “buy” rating and a $33.00 target price on the stock. The Goldman Sachs Group downgraded Apria from a “buy” rating to a “neutral” rating and lowered their target price for the company from $32.00 to $29.00 in a research note on Monday, July 19th. Citigroup upped their price target on Apria from $33.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, August 6th. Finally, Piper Sandler upped their price target on Apria from $33.00 to $35.00 and gave the stock an “overweight” rating in a research note on Friday, August 6th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Apria presently has a consensus rating of “Buy” and an average price target of $31.86.

Apria Company Profile

Apria, Inc provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products.

Featured Story: Hang Seng Index (HSI)

Insider Buying and Selling by Quarter for Apria (NYSE:APR)

Receive News & Ratings for Apria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apria and related companies with MarketBeat.com's FREE daily email newsletter.